跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 29 天前AI 评分48

Gilead支付12.8亿美元首付款引进PepStar口服IL-23药物

Gilead strikes $1.3B upfront China deal for oral IL-23 drug

AI 导读

Gilead将向PepStar Therapeutics支付12.8亿美元首付款,引进其处于临床开发阶段的口服IL-23药物,交易涉及炎症治疗市场。原文正文被订阅墙截断,未给出试验期别与适应症。

正文

Gilead is go­ing to Shang­hai for its lat­est ex­pan­sion in the hot in­flam­ma­tion mar­ket, dish­ing out $1.28 bil­lion up­front to Pep­Star Ther­a­peu­tics for a Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news